- Home
- IMUX
IMUX
Immunic Inc.
as 07-26-2024 4:00pm EST
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 114.4M | IPO Year: | N/A |
| Target Price: | $15.00 | AVG Volume (30 days): | 392.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.94 - $2.45 | Next Earning Date: | 08-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Immunic Inc. (IMUX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Vitt Daniel | IMUX | President and CEO | Feb 26 '24 | Buy | $1.31 | 14,000 | $18,333.00 | 390,877 | SEC Form 4 |
Latest Immunic Inc. News
IMUX Breaking Stock News: Dive into IMUX Ticker-Specific Updates for Smart Investing
PR Newswire
3 days ago
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
MT Newswires
17 days ago
Immunic Names Jason Tardio as COO, Werner Gladdines as Chief Development Officer
PR Newswire
18 days ago
Immunic Appoints Jason Tardio as Chief Operating Officer and President
Business Wire
2 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
GlobeNewswire
2 months ago
Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
GlobeNewswire
2 months ago
Share buy-back programme - week 23
Simply Wall St.
2 months ago
Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
Reuters
2 months ago
Japan's service sector mood hits nearly 2-year low in May
Compare IMUX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMUX Immunic Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.